CD8A and myeloid sarcoma: Data from Gaiha and colleagues, demonstrating that rituximab-treated MS patients have lower preexisting antiviral CD8+ T cell immunity as measured by stimulation of PBMCs with a combination of CMV, EBV, and flu (CEF) peptides (12), further suggest that this deficiency extends to generating long-lived memory following infection.